419 related articles for article (PubMed ID: 11204935)
21. Piroxicam immediate release formulations: A fasting randomized open-label crossover bioequivalence study in healthy volunteers.
Helmy SA; El-Bedaiwy HM
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):466-71. PubMed ID: 27129120
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma.
Day RO; Williams KM; Graham S; Handel M
Arthritis Rheum; 1991 Jun; 34(6):751-60. PubMed ID: 2053921
[TBL] [Abstract][Full Text] [Related]
23. Oral tenoxicam for peripheral orthopaedic surgery: a pharmacokinetic study.
Blake DW; Bjorksten AR; Libreri FC
Anaesth Intensive Care; 1997 Apr; 25(2):142-6. PubMed ID: 9127656
[TBL] [Abstract][Full Text] [Related]
24. Tenoxicam used as a parenteral formulation for acute pain in rheumatic conditions.
Jeunet F; Enz W; Guentert T
Scand J Rheumatol Suppl; 1989; 80():59-61. PubMed ID: 2595344
[TBL] [Abstract][Full Text] [Related]
25. Intranasal delivery of tenoxicam in rat.
Raghavan CV; Abimon VD
Int J Pharm; 2001 Jun; 221(1-2):227-9. PubMed ID: 11397584
[TBL] [Abstract][Full Text] [Related]
26. Quality of life assessment during six months of NSAID treatment [Gonarthrosis and Quality of Life (GOAL) Study].
La Montagna G; Tirri G; Cacace E; Perpignano G; Covelli M; Pipitone V; D'Agostino P; Magarò M; Ferraccioli G; Mascia MT; Manzini E; Minari C; Barreca C; Marcolongo R; Paresce E; Colombo B
Clin Exp Rheumatol; 1998; 16(1):49-54. PubMed ID: 9543561
[TBL] [Abstract][Full Text] [Related]
27. Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis.
Nichol FE; Samanta A; Rose CM
Drugs; 1988; 35 Suppl 1():46-51. PubMed ID: 3359945
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic study on piroxicam at the steady-state in elderly subjects and younger adults after administration of piroxicam beta-cyclodextrin.
Acerbi D; Bonati C; Boscarino G; Bufalino L; Cesari F; D'Ambrosio E; Mansanti P; Scali G
Int J Clin Pharmacol Res; 1988; 8(3):175-80. PubMed ID: 3403105
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of piroxicam-beta-cyclodextrin in the outpatient management of chronic back pain.
Pijak MR; Turcani P; Turcaniova Z; Buran I; Gogolak I; Mihal A; Gazdik F
Bratisl Lek Listy; 2002; 103(12):467-72. PubMed ID: 12696775
[TBL] [Abstract][Full Text] [Related]
30. Transdermal lontophoresis and skin retention of piroxicam from gels containing piroxicam: hydroxypropyl-beta-cyclodextrin complexes.
Doliwa A; Santoyo S; Ygartua P
Drug Dev Ind Pharm; 2001 Sep; 27(8):751-8. PubMed ID: 11699826
[TBL] [Abstract][Full Text] [Related]
31. Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.
Bartlett A; Costa A; Martinez L; Roser R; Sagarra R; Sanchez J
Eur J Drug Metab Pharmacokinet; 1992; 17(3):195-9. PubMed ID: 1490488
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis.
Caldwell JR
Clin Ther; 1994; 16(2):222-35. PubMed ID: 8062318
[TBL] [Abstract][Full Text] [Related]
33. [Synovial tissue levels in comparison with synovial fluid and serum concentrations following a single daily administration of 20 mg piroxicam (Felden)].
Thabe H; Fassbender HG; Laufen H; Gierend M
Z Rheumatol; 1986; 45(5):271-6. PubMed ID: 3811635
[TBL] [Abstract][Full Text] [Related]
34. Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection.
Kim SR; Ho MJ; Kim SH; Cho HR; Kim HS; Choi YS; Choi YW; Kang MJ
Drug Des Devel Ther; 2016; 10():3779-3787. PubMed ID: 27895468
[TBL] [Abstract][Full Text] [Related]
35. Plasma tenoxicam concentrations after single and multiple oral doses.
Crevoisier C; Heizmann P; Forgo I; Dubach UC
Eur J Drug Metab Pharmacokinet; 1989; 14(1):23-7. PubMed ID: 2788089
[TBL] [Abstract][Full Text] [Related]
36. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect.
Dalmora ME; Dalmora SL; Oliveira AG
Int J Pharm; 2001 Jul; 222(1):45-55. PubMed ID: 11404031
[TBL] [Abstract][Full Text] [Related]
37. Piroxicam-β-cyclodextrin: a GI safer piroxicam.
Scarpignato C
Curr Med Chem; 2013; 20(19):2415-37. PubMed ID: 23394552
[TBL] [Abstract][Full Text] [Related]
38. Rheumatic diseases--clinical experience with piroxicam-beta-cyclodextrin.
Serni U
Eur J Rheumatol Inflamm; 1993; 12(4):47-54. PubMed ID: 7805704
[TBL] [Abstract][Full Text] [Related]
39. Studies of piroxicam absorption by oral mucosa.
Diez-Ortego I; Cruz M; Largo R; Navarro A; Palacios I; Solans A; Sanchez-Pernaute O; Egido J; Herrero-Beaumont G
Arzneimittelforschung; 2002; 52(5):385-7. PubMed ID: 12087924
[TBL] [Abstract][Full Text] [Related]
40. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.
Day RO; Francis H; Vial J; Geisslinger G; Williams KM
J Rheumatol; 1995 Dec; 22(12):2295-303. PubMed ID: 8835565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
